Cyxone AB-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Cyxone AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014164
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company’s lead product include T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. It also offers cyclotides, a new class of highly specific low toxicity drugs that can be used for several immune-related diseases and cancers. Cyxone collaborates with other medical universities for the development of cyclotide. The company also conducts preclinical studies and phase I clinical trials. It operates across Austria and Germany. Cyxone is headquartered in Malmo, Sweden.

Cyxone AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cyxone AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Cyxone to Acquire Rights of Rabeximod from Oxypharma 10
Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11
Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12
Partnerships 13
Cyxone Partners with Medical University of Vienna 13
Cyxone Enters into Agreement with University of Queensland 14
Cyxone Enters into Agreement with Sourcia 15
Cyxone Enters into Agreement with Bachem 16
Cyxone AB – Key Competitors 17
Cyxone AB – Key Employees 18
Cyxone AB – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Oct 26, 2017: Cyxone: Interim report July 1 to September 30, 2017 20
Aug 30, 2017: Cyxone: Interim report 2017-01-01 to 2017-06-30 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Cyxone AB, Pharmaceuticals & Healthcare, Key Facts 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cyxone AB, Deals By Therapy Area, 2011 to YTD 2017 8
Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cyxone to Acquire Rights of Rabeximod from Oxypharma 10
Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11
Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12
Cyxone Partners with Medical University of Vienna 13
Cyxone Enters into Agreement with University of Queensland 14
Cyxone Enters into Agreement with Sourcia 15
Cyxone Enters into Agreement with Bachem 16
Cyxone AB, Key Competitors 17
Cyxone AB, Key Employees 18

★海外企業調査レポート[Cyxone AB-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CME Group Inc.:戦略・SWOT・企業財務分析
    CME Group Inc. - Strategy, SWOT and Corporate Finance Report Summary CME Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Mindteck (India) Limited:戦略・SWOT・企業財務分析
    Mindteck (India) Limited - Strategy, SWOT and Corporate Finance Report Summary Mindteck (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Medical Developments International Ltd (MVP):製薬・医療:M&Aディール及び事業提携情報
    Summary Medical Developments International Ltd (MDI) is a healthcare company that develops, manufactures and markets pain relief and respiratory medicine. The company provides products such as penthrox, asthma and COPD, medical devices and veterinary products. It offers asthma and COPD products whic …
  • Banco Pan SA (BPAN4):企業の財務・戦略的SWOT分析
    Banco Pan SA (BPAN4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ISA Pharmaceuticals BV:製薬・医療:M&Aディール及び事業提携情報
    Summary ISA Pharmaceuticals BV (ISA Pharmaceuticals) is a developer of synthetic therapeutic vaccines for the treatment of cancer and persistent viral infections. The company’s pipeline products include ISA101, an immunotherapeutic vaccine for cervical cancer; MyISA, a personalized immunotherapy bas …
  • Bezeq The Israel Telecommunication Corp. Ltd. (BEZQ):企業の財務・戦略的SWOT分析
    Bezeq The Israel Telecommunication Corp. Ltd. (BEZQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Louisiana-Pacific Corporation:戦略・SWOT・企業財務分析
    Louisiana-Pacific Corporation - Strategy, SWOT and Corporate Finance Report Summary Louisiana-Pacific Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Schlumberger Ltd (SLB):企業の財務・戦略的SWOT分析
    Schlumberger Ltd (SLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • St. Barbara Limited:企業のM&A・事業提携・投資動向
    St. Barbara Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's St. Barbara Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Innoviva Inc (INVA):企業の財務・戦略的SWOT分析
    Innoviva Inc (INVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • BOE Technology Group Co Ltd:企業の戦略・SWOT・財務情報
    BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Hisamitsu Pharmaceutical Co Inc (4530):製薬・医療:M&Aディール及び事業提携情報
    Summary Hisamitsu Pharmaceutical Co Inc (Hisamitsu Pharmaceutical) is a pharmaceutical company that provides pain management products. The company manufactures and sells pain relieving products, dermatological products, and quasi drugs, among others. Hisamitsu Pharmaceutical provides its products in …
  • Grupo Grana y Montero SAA (GRAMONC1):企業の財務・戦略的SWOT分析
    Grupo Grana y Montero SAA (GRAMONC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Strukton Groep Nv:企業の戦略・SWOT・財務分析
    Strukton Groep Nv - Strategy, SWOT and Corporate Finance Report Summary Strukton Groep Nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Desitin Arzneimittel GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Desitin Arzneimittel GmbH (Desitin), formerly Desitin Compagnie mbH is a healthcare products provider that offers therapeutic products. The company develops and markets products for the treatment of neurological and psychiatric illnesses. It provides products for various therapeutic areas su …
  • Midshire Catering Services Limited:企業の戦略・SWOT・財務情報
    Midshire Catering Services Limited - Strategy, SWOT and Corporate Finance Report Summary Midshire Catering Services Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • AutoNation Inc (AN):企業の財務・戦略的SWOT分析
    AutoNation Inc (AN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • eBay Inc:戦略・SWOT・企業財務分析
    eBay Inc - Strategy, SWOT and Corporate Finance Report Summary eBay Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • DiscGenics Inc-製薬・医療分野:企業M&A・提携分析
    Summary DiscGenics Inc (DiscGenics) is a biotechnology company that develops advanced spinal therapeutics. The company develops therapies to treat patients with intervertebral disc diseases. Its products comprise Injectable Discogenic Cell Therapy (IDCT), developed for treating patients with moderat …
  • Australian Vanadium Ltd (YRR):企業の財務・戦略的SWOT分析
    Summary Australian Vanadium Ltd (AVL), formerly Yellow Rock Resources Ltd, is a mining company that explores and develops titanium, vanadium, copper, gold, and uranium metals. The company’s projects include Gabanintha Gold Copper Project, The Australian Vanadium Project, Coates Vanadium Project, Now …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆